The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6602267.pdf
Reference23 articles.
1. Antman KH (2001) A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur J Cancer 37: 173–179
2. Baynes RD, Dansey RD, Klein JL, Hamm C, Campbell M, Abella E, Peters WP (2001) High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 28: 377–388
3. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384–1391
4. Box GP, Draper NR (1987) Empirical Model Building and Response Surfaces. New York: John Wiley & Sons
5. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205–1211
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling;Breast Cancer Research and Treatment;2016-01
2. Y-Box–Binding Protein YB-1 Identifies High-Risk Patients With Primary Breast Cancer Benefiting From Rapidly Cycled Tandem High-Dose Adjuvant Chemotherapy;Journal of Clinical Oncology;2009-12-20
3. Immunology and the Role of Immunotherapy in Breast Cancer;The Breast;2009
4. Insulin-like Growth Factor–Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer;Cancer Research;2008-10-15
5. Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity;Breast Cancer Research and Treatment;2008-01-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3